Literature DB >> 12151975

Prognostic factors of reirradiation for recurrent head and neck cancer.

Yukio Ohizumi1, Yoshifumi Tamai, Satoshi Imamiya, Takeshi Akiba.   

Abstract

We analyzed outcomes and prognostic factors to assess the value of reirradiation for recurrent head and neck cancer. Forty-four patients with recurrent squamous-cell carcinoma had undergone external beam reirradiation with cumulative dosing of more than 80 Gy. Six and 38 cases exhibited recurrent stage III and stage IV cancers, respectively. The complete response rate was 32%. Median relapse-free survival time was 4 months, and the 5-year survival was 6%. The major prognostic factor was anatomical location (p < 0.0001). Favorable sites were the nasopharynx, larynx, or oropharynx; unfavorable sites were the oral cavity, nasal cavity, or hypopharynx. Poorly differentiated cancer, no prior surgery, cumulative dose more than 125 Gy, and overlapping field less than 40 cm2 between the initial and reirradiation fields were also favorable factors. Multivariate analysis revealed that anatomical location and overlapping field were significant (0.001 and 0.019, respectively) in relapse-free survival. On exclusion of anatomical location from the analysis, history of prior surgery, and cumulative dose were significant (p = 0.002 and p = 0.023, respectively). Severe late complications occurred in only 1 of 14 (7%) patients followed up for longer than 1 year. Reirradiation would be indicative for nasopharyngeal, oropharyngeal, or laryngeal cancer with small overlapping field, or cancer receiving a cumulative dose more than 125 Gy without prior surgery.

Entities:  

Mesh:

Year:  2002        PMID: 12151975     DOI: 10.1097/00000421-200208000-00018

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  7 in total

1.  Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy.

Authors:  Hideya Yamazaki; Yusuke Demizu; Tomoaki Okimoto; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Ken Yoshida; Tadayuki Kotsuma; Yasuo Yoshioka; Ryoongjin Oh
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

Review 2.  Reirradiation of head and neck cancer focusing on hypofractionated stereotactic body radiation therapy.

Authors:  Hideya Yamazaki; Naohiro Kodani; Mikio Ogita; Kengo Sato; Kengo Himei
Journal:  Radiat Oncol       Date:  2011-08-21       Impact factor: 3.481

3.  Reirradiation using robotic image-guided stereotactic radiotherapy of recurrent head and neck cancer.

Authors:  Hideya Yamazaki; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Ken Yoshida; Tadayuki Kotsuma; Yasuo Yoshioka
Journal:  J Radiat Res       Date:  2016-03-16       Impact factor: 2.724

Review 4.  Reirradiation of head and neck cancer in the era of intensity-modulated radiotherapy: patient selection, practical aspects, and current evidence.

Authors:  Yeon Sil Kim
Journal:  Radiat Oncol J       Date:  2017-03-31

5.  Cyberknife Radiosurgery for the Treatment of Head and Neck Cancer: A Systematic Review.

Authors:  Cristalle Soman; Shahad Ramzi Mohammed Alghamdi; Faisal Nahar M Alazemi; Abdulaziz Ahmad Abdullah Alghamdi
Journal:  Eur J Dent       Date:  2021-12-10

6.  Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic.

Authors:  Kelly K Curtis; Helen J Ross; Ashley L Garrett; Theresa A Jizba; Ajay B Patel; Samir H Patel; William W Wong; Michele Y Halyard; Stephen J Ko; Heidi E Kosiorek; Robert L Foote
Journal:  Radiat Oncol       Date:  2016-04-09       Impact factor: 3.481

7.  The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.

Authors:  Alexander Rühle; Tanja Sprave; Tobias Kalckreuth; Raluca Stoian; Erik Haehl; Constantinos Zamboglou; Roland Laszig; Andreas Knopf; Anca-Ligia Grosu; Nils H Nicolay
Journal:  Radiat Oncol       Date:  2020-04-16       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.